BCL2 and hematopoietic and lymphoid cell neoplasm: Importantly, combinatorial targeting of BCL-2 and MCL-1 is tolerated in mice and is under investigation in clinical trials of hematological cancers (NCT03672695, NCT04702425) [111–114].